Search Result

Results for "

Soluble epoxide hydrolase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Epoxide Hydrolase (63) FAAH (1) Apoptosis (2) Autophagy (2) CaMK (2) Cholinesterase (ChE) (6) COX (1) Drug Metabolite (1) Endogenous Metabolite (2) FLAP (2) Fluorescent Dye (1) FXR (1) HDAC (1) Interleukin Related (5) Isotope-Labeled Compounds (1) NF-κB (1) NOD-like Receptor (NLR) (1) PGE synthase (1) PPAR (4) PROTACs (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) TNF Receptor (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (25) Infection (3) Inflammation/Immunology (40) Metabolic Disease (14) Neurological Disease (18)

Inhibitors & Agonists

Fluorescent Dyes

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Epoxide Hydrolase VKOR FAAH S-adenosylhomocysteine hydrolase (SAHH) Carboxylesterase (CES) OGA Hormone-Sensitive Lipase (HSL)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101294

TPPU Maximum Cited Publications 14 Publications Verification	Epoxide Hydrolase	Inflammation/Immunology
TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC₅₀ values of 37 and 3.7 nM for monkey and human sEH, respectively.

HY-113974

trans-AUCB 2 Publications Verification t-AUCB	Epoxide Hydrolase	Cancer
trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity .

HY-128171

Diflapolin 1 Publications Verification	FLAP Epoxide Hydrolase	Inflammation/Immunology
Diflapolin is a highly active dual 5-lipoxygenase-activating protein *(FLAP)*/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC₅₀s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC₅₀=20?nM) .

HY-108570

AUDA 3 Publications Verification	Epoxide Hydrolase	Inflammation/Immunology
AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 18 and 69 nM for the mouse and human sEH, respectively . AUDA has anti-inflammatory activity .

HY-135653

EC5026 1 Publications Verification BPN-19186	Epoxide Hydrolase	Neurological Disease
EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain .

HY-19644

GSK2256294A 2 Publications Verification GSK 2256294	Epoxide Hydrolase	Cardiovascular Disease
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC₅₀s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .

HY-124063

BI-1935 1 Publications Verification	Epoxide Hydrolase	Cardiovascular Disease
BI-1935, a chemical probe, is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease .

HY-113489

14,15-Epoxyeicosatrienoic acid 14,15-EET	Endogenous Metabolite	Cardiovascular Disease Neurological Disease
14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research .

HY-121538

CUDA 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-111151

AR-9281 APAU	Epoxide Hydrolase	Infection Cardiovascular Disease Metabolic Disease
AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC₅₀ values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .

HY-114266

UC-1728 t-TUCB	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 2 nM on rabbit liver.

HY-N0805A

Alisol B 1 Publications Verification	Epoxide Hydrolase CaMK Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a K_i of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G₁ phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer .

HY-126326

SWE101	Epoxide Hydrolase	Metabolic Disease
SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC₅₀s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH .

HY-119684

Maresin 2	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury .

HY-120494

sEH inhibitor-1	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC₅₀s of 0.4 and 5.3 nM in human and murine, respectively .

HY-W013989

1,3-Dicyclohexylurea	Epoxide Hydrolase	Cardiovascular Disease
1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats .

HY-113111

11,12-DiHETrE	Drug Metabolite	Inflammation/Immunology
11,12-DiHETrE is a dihydroxy fatty acid metabolite of Arachidonic Acid (HY-109590). 11,12-DiHETrE is converted to 11,12-DiHETrE under elevated soluble epoxide hydrolase (sEH) activity, a process closely related to inflammation and oxidative stress. 11,12-DiHETrE can serve as a single biomarker to differentiate between NAFL (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). 11,12-DiHETrE can be used in studies on preterm birth, autism, and pulmonary hypertension .

HY-148136

sEH inhibitor-7	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
sEH inhibitor-7 (compound c-2) is an inhibitor of soluble **epoxide hydrolase (sEH) with IC₅₀s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH**) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation .

HY-U00453

Soluble epoxide hydrolase inhibitor	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease
Soluble epoxide hydrolase inhibitor is an inhibitor of **soluble epoxide hydrolase*, and inhibits human soluble* epoxide hydrolase (h-sEH) with pIC₅₀ of 8.4, extracted from patent WO 2010096722 A1, example 57.

HY-W013989R

1,3-Dicyclohexylurea (Standard)	Reference Standards Epoxide Hydrolase	Cardiovascular Disease
1,3-Dicyclohexylurea (Standard) is the analytical standard of 1,3-Dicyclohexylurea. This product is intended for research and analytical applications. 1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats .

HY-121538A

CUDA disodium 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .

HY-N17669

4H-Tomentosin	Epoxide Hydrolase	Cardiovascular Disease
4H-Tomentosin is a mixed-competitive type soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 6.84 μM and a K_i of 7.02 μM. 4H-Tomentosin interacts with sEH by forming hydrogen bonds with Tyr343, Ile363, and Tyr383 .

HY-144738

Dual FAAH/sEH-IN-1	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

HY-178434

BRP-821 FP30	Epoxide Hydrolase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
BRP-821 is a **soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀** of 0.4 nM. BRP-821 can be used for the researches of inflammation, cardiovascular, metabolic and neurological disease .

HY-179166

PROTAC sEH-degrader-4	PROTACs Epoxide Hydrolase	Inflammation/Immunology
PROTAC sEH-degrader-4 is a highly efficient PROTAC degrader that targets soluble epoxide hydrolase (sEH) (pDC₅₀ = 10.3). PROTAC sEH-degrader-4 can be used for research on inflammation-related diseases. Pink: sEH ligand (HY-179169); Blue: E3 ligase CRBN ligand (HY-179168); Black: Linker .

HY-W403075

N-(3-Methoxybenzyl)stearamide	Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC₅₀s of 0.001 and <0.001 μg/nM, respectively .

HY-135795

1-Cyclohexyl-3-dodecyl urea CDU; N-Cyclohexyl-N-dodecyl urea; NCND	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease
1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective soluble epoxide hydrolase (sEH) inhibitor. 1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) increases epoxyeicosatrienoic acids (EETs) levels and lowers blood pressure in angiotensin II (Ang II) hypertension .

HY-148000

sEH inhibitor-6	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 0.5 nM .

HY-151621

sEH inhibitor-13	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 0.4 μM .

HY-173443

SP-C01	PPAR Epoxide Hydrolase	Metabolic Disease Inflammation/Immunology
SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation .

HY-179441

sEH/FLAP-IN-2	Epoxide Hydrolase FLAP	Inflammation/Immunology
sEH/FLAP-IN-2 is a selective sEH (IC₅₀ = 12.6 nM)/FLAP dual inhibitor. sEH/FLAP-IN-2 highlights the reduction of 5-LOX/FLAP- and sEH-derived LMs, resulting in a favourable redistribution of LMs. sEH/FLAP-IN-2 can be used for the study of peritonitis .

HY-108570R

AUDA (Standard)	Epoxide Hydrolase	Inflammation/Immunology
AUDA (Standard) is the analytical standard of AUDA. This product is intended for research and analytical applications. AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively . AUDA has anti-inflammatory activity .

HY-159171

sEH/HDAC6-IN-2	Epoxide Hydrolase HDAC	Neurological Disease Inflammation/Immunology
sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC₅₀s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain .

HY-W587945

(E)-3-Feruloylquinic acid (E)-3-O-Feruloylquinic acid	Epoxide Hydrolase	Cardiovascular Disease
(E)-3-Feruloylquinic acid (Compound 3) is a chlorogenic acid. (E)-3-Feruloylquinic acid can be isolated from the aerial parts of Tetrastigma hemsleyanum. (E)-3-Feruloylquinic acid inhibits soluble epoxide hydrolase (sEH) with an IC₅₀ of 60.7 μM. (E)-3-Feruloylquinic acid can be used in the study of vascular system diseases .

HY-174443

PROTAC sEH degrader-2	PROTACs Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
PROTAC sEH degrader-2 is a PROTAC targeting degradation agent for **soluble epoxide hydrolase (sEH**) with pIC₅₀ values of the catalytic domain of 8.37 (human sEH-H) and 7.12 (mouce sEH-H). PROTAC sEH degrader-2 can be used for the research related to inflammation and neuroinflammation, such as Alzheimer's disease . (Structure Note: Pink: sEH-H ligand (HY-174225); Blue: CRBN Ligand (HY-103597); Black: linker; E3 + linker (HY-141011))

HY-N16648

sEH-IN-22	Epoxide Hydrolase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
sEH-IN-22 (Compound 1) is a **soluble epoxide hydrolase (sEH) inhibitor (IC₅₀** = 1.1 μM) found in Rubia philippinensis. sEH-IN-22 exhibits anti-inflammatory, analgesic and blood pressure-regulating effects. sEH-IN-22 can be used for the researches of inflammation, neurological and cardiovascular disease .

HY-145833A

sEH/AChE-IN-4	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .

HY-145833

sEH/AChE-IN-3	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .

HY-111151R

AR-9281 (Standard) APAU (Standard)	Epoxide Hydrolase Reference Standards	Infection Cardiovascular Disease Metabolic Disease
AR-9281 (Standard) is the analytical standard of AR-9281. This product is intended for research and analytical applications. AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .

HY-W097200

1,3-Dibenzylurea N,N′-Dibenzylurea	Epoxide Hydrolase	Others
1,3-Dibenzylurea is an insect growth regulator and a mouse soluble epoxide hydrolase (MsEH) inhibitor .

HY-168144

DJ-53	Epoxide Hydrolase	Cancer
DJ-53 (compund 68) is an orally active phenylquinoline-based soluble epoxide hydrolase inhibitor .

HY-147733

sEH inhibitor-5	Cholinesterase (ChE)	Inflammation/Immunology
sEH inhibitor-5 (compound D016) is a potent sEH (soluble epoxide hydrolase) inhibitor with an IC₅₀ value of 0.1 nM .

HY-146643

sEH inhibitor-3	Epoxide Hydrolase	Neurological Disease
sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a K_i of 0.75 nM for human sEH .

HY-126041A

(±)10(11)-EpDPA (±)10,11-EDP; (±)10,11-EpDPE; (±)10,11-Epoxy docosapentaenoic acid	Epoxide Hydrolase	Metabolic Disease
(±)10(11)-EpDPA, a docosahexaenoic acid epoxygenase metabolite, acts as a substrate for soluble epoxide hydrolase (sEH) with a K_m value of 5.1 µM for human sEH .

HY-N12528

10,11-EDT	Epoxide Hydrolase	Cardiovascular Disease
10,11-EDT, a soluble epoxide hydrolase (sEH) substrate, is a metabolic product of adrenic acid. 10,11-EDT is an endothelium-derived hyperpolarizing factor with strong vasorelaxant effects .

HY-121941

Epoxy Fluor 7	Fluorescent Dye	Others
Epoxy Fluor 7 is a sensitive fluorescent substrate for soluble epoxide hydrolase (sEH) that can be used for human and mouse enzymes. Epoxy Fluor 7 is hydrolyzed to yield fluorescence used for monitoring the activity of sEH.

HY-147732

sEH inhibitor-4	Epoxide Hydrolase	Inflammation/Immunology
Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.

HY-159121

sEH inhibitor-17	Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC₅₀ of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy .

HY-174327

sEH-IN-3	Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
sEH-IN-3 (Compound 50) is a soluble epoxide hydrolase (sEH) inhibitor (IC₅₀: 0.46 nM). sEH-IN-3 can maintain the anti-inflammatory and analgesic activities of epoxyeicosatrienoic acids (EETs) .

HY-160676

sEH-IN-1	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0805A

Alisol B 1 Publications Verification	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Metabolic Disease Alismataceae Plants Disease Research Fields Source Classification	Epoxide Hydrolase CaMK Autophagy Apoptosis
Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a K_i of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G₁ phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer .

HY-N17669

4H-Tomentosin	Structural Classification Terpenoids Sesquiterpenes Inula helenium L. Plants Compositae Source Classification	Epoxide Hydrolase
4H-Tomentosin is a mixed-competitive type soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 6.84 μM and a K_i of 7.02 μM. 4H-Tomentosin interacts with sEH by forming hydrogen bonds with Tyr343, Ile363, and Tyr383 .

HY-W587945

(E)-3-Feruloylquinic acid (E)-3-O-Feruloylquinic acid	Monophenols Tetrastigma hemsleyanum Diels et Gilg Phenols Plants Vitaceae Source Classification	Epoxide Hydrolase
(E)-3-Feruloylquinic acid (Compound 3) is a chlorogenic acid. (E)-3-Feruloylquinic acid can be isolated from the aerial parts of Tetrastigma hemsleyanum. (E)-3-Feruloylquinic acid inhibits soluble epoxide hydrolase (sEH) with an IC₅₀ of 60.7 μM. (E)-3-Feruloylquinic acid can be used in the study of vascular system diseases .

HY-N16648

sEH-IN-22	Structural Classification Ketones, Aldehydes, Acids Rubia philippinensis Elmer Rubiaceae Plants Source Classification	Epoxide Hydrolase
sEH-IN-22 (Compound 1) is a **soluble epoxide hydrolase (sEH) inhibitor (IC₅₀** = 1.1 μM) found in Rubia philippinensis. sEH-IN-22 exhibits anti-inflammatory, analgesic and blood pressure-regulating effects. sEH-IN-22 can be used for the researches of inflammation, neurological and cardiovascular disease .

HY-N12528

10,11-EDT	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Epoxide Hydrolase
10,11-EDT, a soluble epoxide hydrolase (sEH) substrate, is a metabolic product of adrenic acid. 10,11-EDT is an endothelium-derived hyperpolarizing factor with strong vasorelaxant effects .

HY-N0805AR

Alisol B (Standard)	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Alismataceae Plants Source Classification	Reference Standards Epoxide Hydrolase CaMK Autophagy Apoptosis
Alisol B (Standard) is the analytical standard of Alisol B (HY-N0805A). This product is intended for research and analytical applications. Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a K_i of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.

Cat. No.	Product Name	Chemical Structure

HY-121538S

CUDA-d11
CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Soluble epoxide hydrolase

Inhibitors & Agonists

Fluorescent Dyes

NaturalProducts

Isotope-Labeled Compounds

Natural
Products